Current treatment of non‐alcoholic fatty liver disease

Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis

(2022) Grazia Pennisi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

(2021) Alessandro Mantovani et al.   Metabolites

Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study

(2021) Tracey G. Simon et al.   HEPATOLOGY

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial

(2021) Samer Gawrieh et al.   HEPATOLOGY

FXR agonists for NASH: How are they different and what difference do they make?

(2021) Claus Kremoser   JOURNAL OF HEPATOLOGY

Non-alcoholic fatty liver disease

(2021) Elizabeth E Powell et al.   LANCET

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

(2021) Giovanni Targher et al.   Lancet Gastroenterology & Hepatology

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

(2021) Rajaa Nahra et al.   DIABETES CARE

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease

(2021) Fasiha Kanwal et al.   GASTROENTEROLOGY

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

(2021) Stephen A. Harrison et al.   NATURE MEDICINE

Novel therapeutic targets for cholestatic and fatty liver disease

(2021) Michael Trauner et al.   GUT

Baveno VII – Renewing consensus in portal hypertension

(2021) Roberto de Franchis et al.   JOURNAL OF HEPATOLOGY

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials

(2020) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

SGLT2 inhibitors in liver patients

(2020) John Chen Hsiang et al.   Clinical Gastroenterology and Hepatology

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

(2020) Mark L. Hartman et al.   DIABETES CARE

Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology

(2020) James Neuberger et al.   GUT

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

(2020) Stephen A. Harrison et al.   GASTROENTEROLOGY

Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy

(2020) Judith Stift et al.   DIGESTIVE AND LIVER DISEASE

Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial

(2020) Rohit Loomba et al.   JOURNAL OF HEPATOLOGY

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

(2020) Rohit Loomba et al.   HEPATOLOGY

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma

(2019) Lena Schulte et al.   LIVER INTERNATIONAL

Elastography-based screening for esophageal varices in patients with advanced chronic liver disease

(2019) Rafael Paternostro et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information

(2019) Judith Stift et al.   DIGESTIVE AND LIVER DISEASE

Sarcopenic obesity in fatty liver

(2019) Manuela Merli et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial

(2019) Fernando Bril et al.   DIABETES CARE

Noninvasive tests accurately identify advanced fibrosis due to NASH : Baseline data from the STELLAR trials

(2019) Quentin M. Anstee et al.   HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study

(2018) R. Schwarzer et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes

(2018) Fernando Bril et al.   Clinical Gastroenterology and Hepatology

Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers

(2018) Eduardo Vilar-Gomez et al.   JOURNAL OF HEPATOLOGY

Clinical states of cirrhosis and competing risks

(2018) Gennaro D'Amico et al.   JOURNAL OF HEPATOLOGY

Ruling out esophageal varices in NAFLD cirrhosis: Can we do without endoscopy?

(2018) Roberto de Franchis et al.   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

(2018) Paolo Angeli et al.   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis

(2018) Eduardo Vilar-Gomez et al.   HEPATOLOGY

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

(2018) Arun Sanyal et al.   LANCET

Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease

(2017) Salvador Augustin et al.   HEPATOLOGY

Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study

(2017) Annalisa Berzigotti et al.   HEPATOLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

Development of a novel frailty index to predict mortality in patients with end-stage liver disease

(2017) Jennifer C. Lai et al.   HEPATOLOGY

Beta adrenergic blockade and decompensated cirrhosis

(2017) Thomas Reiberger et al.   JOURNAL OF HEPATOLOGY

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

(2017) Hannes Hagström et al.   JOURNAL OF HEPATOLOGY

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World

(2016) Mehmet Sayiner et al.   Clinics in Liver Disease

Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis

(2016) Juan G. Abraldes et al.   GASTROENTEROLOGY

Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality

(2016) Zobair Younossi et al.   GASTROENTEROLOGY

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis

(2016) Mehmet Sayiner et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices

(2016) James B Maurice et al.   JOURNAL OF HEPATOLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Sarcopenia from mechanism to diagnosis and treatment in liver disease

(2016) Srinivasan Dasarathy et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Changes in Hepatic Venous Pressure Gradient Induced by Physical Exercise in Cirrhosis: Results of a Pilot Randomized Open Clinical Trial

(2016) Ricardo U Macías-Rodríguez et al.   Clinical and Translational Gastroenterology

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Nonselective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis

(2014) Mattias Mandorfer et al.   GASTROENTEROLOGY

Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery

(2013) L. Sjöström   JOURNAL OF INTERNAL MEDICINE

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

(2012) G. Musso et al.   DIABETOLOGIA

Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients

(2012) Pierre Bedossa et al.   HEPATOLOGY

Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects

(2011) Sven Haufe et al.   HEPATOLOGY

Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes

(2010) M. Lazo et al.   DIABETES CARE

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

(2010) Elizabeth M. Brunt et al.   HEPATOLOGY

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dietary Fat and Carbohydrates Differentially Alter Insulin Sensitivity During Caloric Restriction

(2009) Erik Kirk et al.   GASTROENTEROLOGY